ABCB1 p.Gly211Ala

[switch to full view]
Comments [show]
Publications
PMID: 12769780 [PubMed] Toffoli G et al: "Pharmacogenetics of irinotecan."
No. Sentence Comment
189 The mutation G211A (UGT1A1*6) has a meaningful role in the Asian population where is more widespread than in Caucasians [86].
X
ABCB1 p.Gly211Ala 12769780:189:13
status: NEW
Login to comment

190 UGT1A1*6 allele is characterised by a mutation on exon 1 (G211A) so it has an effect on the protein sequence leading to the aminoacid substitution Gly71Arg.
X
ABCB1 p.Gly211Ala 12769780:190:58
status: NEW
Login to comment

217 UGT1A1 Polymorphisms Involved in Gilbert Syndrome Polymorphism Mutation Effect Location UGT1A1*28 (TA)6→(TA)7 lower expression Promoter UGT1A1*6 G211A Gly71Arg Exon 1 UGT1A1*27 C686A Pro229Gln Exon1 UGT1A1*29 C1099G Arg367Gly Exon 4 UGT1A1*7 T1456G Tyr486Asp Exon 5 tissues and a sequence homology of 49% only [91].
X
ABCB1 p.Gly211Ala 12769780:217:152
status: NEW
Login to comment

PMID: 20504240 [PubMed] Park WB et al: "Genetic factors influencing severe atazanavir-associated hyperbilirubinemia in a population with low UDP-glucuronosyltransferase 1A1*28 allele frequency."
No. Sentence Comment
31 The UGT1A1*6 polymorphism (G211A, G71R), which is common in some Asians (13%-23%) and rare in Caucasians (0.1%) [3], results in an ~70% reduction in the rate of bilirubin glucuronidation in vitro [11] and is associated with Gilbert syndrome in Asians, irrespective of the UGT1A1*28 allele [6, 12].
X
ABCB1 p.Gly211Ala 20504240:31:27
status: NEW
Login to comment

PMID: 20602612 [PubMed] Grover S et al: "Genetic profile of patients with epilepsy on first-line antiepileptic drugs and potential directions for personalized treatment."
No. Sentence Comment
140 UGT1A1*6 is one of the most common UGT1A1 coding variants, characterized by a G211A transition corresponding to codon 71 in exon 1, which changes glycine to arginine.
X
ABCB1 p.Gly211Ala 20602612:140:78
status: NEW
Login to comment

PMID: 15975613 [PubMed] Brandon EF et al: "Validation of in vitro cell models used in drug metabolism and transport studies; genotyping of cytochrome P450, phase II enzymes and drug transporter polymorphisms in the human hepatoma (HepG2), ovarian carcinoma (IGROV-1) and colon carcinoma (CaCo-2, LS180) cell lines."
No. Sentence Comment
56 (2000), was used to determine the *6 (G211A), *7 (T1456G), *27 (C686A), *28 (A(TA)6TAA to A(TA)7TAA), *33 (A(TA)6TAA to A(TA)5TAA), *34 (A(TA)6TAA to A(TA)8TAA) and *29 (C1099G) polymorphisms in the UGT1A1 gene.
X
ABCB1 p.Gly211Ala 15975613:56:38
status: NEW
Login to comment

55 (2000), was used to determine the *6 (G211A), *7 (T1456G), *27 (C686A), *28 (A(TA)6TAA to A(TA)7TAA), *33 (A(TA)6TAA to A(TA)5TAA), *34 (A(TA)6TAA to A(TA)8TAA) and *29 (C1099G) polymorphisms in the UGT1A1 gene.
X
ABCB1 p.Gly211Ala 15975613:55:38
status: NEW
Login to comment